Bioventus Inc. provided preliminary unaudited earnings guidance for the first quarter of 2022. For the period, the company expects net sales to be in the range of $116.5 million to $118.5 million, reflecting 42% to 45% growth over the prior-year period. Net loss expects to be in the range of $19,000,000 and $19,400,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.38 USD | -2.45% | +0.79% | +21.06% |
05-07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
05-07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.06% | 407M | |
+75.69% | 12.57B | |
-25.35% | 7.28B | |
+15.77% | 7.2B | |
+14.52% | 5.47B | |
-18.50% | 4.73B | |
+14.91% | 4.09B | |
-23.67% | 3.78B | |
+42.93% | 2.3B | |
-0.37% | 2.03B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Provides Preliminary Unaudited Earnings Guidance for the First Quarter of 2022